IGF-I R/IGF1R Antibody (3G5C1) NB110-87052 from Novus Biologicals, a Bio-Techne Brand

Product Specs
ItemIGF-I R/IGF1R Antibody (3G5C1)
CompanyNovus Biologicals, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberNB110-87052
ImmunogenPurified recombinant fragment of IGF1R-Beta (AA: 1101-1367) expressed in E. Coli
NCBI Gene AliasesIGFR, IGFIR, CD221, JTK13
ClonalityMonoclonal
TargetIGF-I R/IGF1R
Conjugate/TagUnconjugated
HostMouse
IsotypeIgG2a
Quantity0.1 ml (also 0.025 ml)
ReactivityHuman
Clone3G5C1
ApplicationsWestern Blot, ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin
FormatAscites
NCBI Full Gene Nameinsulin like growth factor 1 receptor
Brand/TrademarkNovus Biologicals, a Bio-Techne Brand
PurityUnpurified
Molecular Weight96 kDa
Research AreaApoptosis, Cancer
Antibody TypePrimary Antibodies
StorageStore at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles

Specifications/Features

Available conjugates: Unconjugated

Add to Compare List

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: http://www.novusbio.com

(1) IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancerEndocrineJune 1, 2019De Martino MC, van Koetsveld PM, Feelders RA, de Herder WW, Dogan F, Janssen JAMJL, Hofste Op Bruinink D, Pivonello C, Waaijers AM, Colao A, et al.antibodies. The primary monoclonal antibodie to detect IGF1R was purchased from Novus Biologicals (NB110-87052; dilution: 1:500) and the primary polyclonal antibodies to detect IGF2 and IGF2R were purchased from

(2) Two prostate cancer‑associated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA bindingOncology reportsJanuary 1, 2019Wang H, Huang W, Yu X, Li W, Huang Y, Mo Z, Gao Y, Zhou Q, Hu Y.

(3) Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patientsOncotargetDecember 1, 2015Jóri B, Kamps R, Xanthoulea S, Delvoux B, Blok MJ, Van de Vijver KK, de Koning B, Oei FT, Tops CM, Speel EJ, et al.

(4) Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancerTumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineAugust 1, 2015Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH.

(5) Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastasesBMC cancerNovember 22, 2014Jiwa LS, van Diest PJ, Hoefnagel LD, Wesseling J, Wesseling P, Dutch Distant Breast Cancer Metastases Consortium., Moelans CB.

(6) Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imagingCellular oncology (Dordrecht)July 1, 2013Vermeulen JF, van der Wall E, Witkamp AJ, van Diest PJ.

(7) Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signallingMolecular and cellular endocrinologyJanuary 5, 2013Varewijck AJ, Brugts MP, Frystyk J, Goudzwaard JA, Uitterlinden P, Waaijers AM, Feng Y, Dimitrov DS, Lamberts SW, Hofland LJ, et al.

(8) Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancerPloS oneJanuary 1, 2013Vermeulen JF, Kornegoor R, van der Wall E, van der Groep P, van Diest PJ.1∶200; PR (clone PgR636, DAKO) 1∶100; HER2 (SP3, Neomarkers, Duiven, The Netherlands) 1∶100; IGF1-R (NB110-87052, Novus Biologicals, Cambridge, UK) 1∶400; FGFR2 (M01, clone 1G3, Abnova, Heidelberg, Germany) 1∶800;

(9) Immunophenotyping invasive breast cancer: paving the road for molecular imagingBMC cancerJune 13, 2012Vermeulen JF, van Brussel AS, van der Groep P, Morsink FH, Bult P, van der Wall E, van Diest PJ.Netherlands) 1:100; GLUT1 (A3536, DAKO) 1:200; CAIX (ab15086, Abcam, Cambridge, UK) 1:1,000; IGF1-R (NB110-87052, Novus Biologicals, Cambridge, UK) 1:400; TfR (13–6800, Invitrogen, Breda, The Netherlands) 1:300; MUC1

(10) MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptorGutJanuary 1, 2012Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, Guan XY.

Be the First to Write a Review!

Endocrine

IGF-I R/IGF1R Antibody (3G5C1) from Novus Biologicals, a Bio-Techne Brand

Specifications/Features

Novus Biologicals, a Bio-Techne Brand

Citations (10)

Reviews

IGF-I R/IGF1R Antibody (3G5C1) from Novus Biologicals, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map